180 Life Sciences Surges 4.49% on $1.24 Billion Volume Ranking 67th as ETHZilla Rebrand Aligns with Trump Crypto Policies

On Aug. 13, 2025, 180 Life Sciences (ATNF) surged 4.49% with a trading volume of $1.24 billion, ranking 67th in market activity. The biotech firm announced a strategic rebranding to ETHZilla and plans to adopt an Ethereum treasury strategy, holding nearly $350 million in ETH and intending to increase its position. The move aligns with broader market optimism around crypto-friendly policies under the Trump administration, which has driven Ethereum's price near record highs above $4,700 year-to-date.

The company’s pivot from chronic pain therapeutics to cryptocurrency treasury management marks a dramatic shift in business focus. While the stock initially spiked over 70% on Wednesday before retracing, its year-to-date gains now exceed 500%. The strategy mirrors approaches taken by high-profile crypto investors, though ETHZilla’s approach remains distinct in its exclusive focus on Ethereum. The decision to rebrand and reallocate capital underscores the growing institutional interest in digital assets as a strategic reserve asset class.

Backtesting of a high-volume trading strategy from 2022 to 2025 showed a compound annual growth rate of 6.98% with a maximum drawdown of 15.59%. While the approach demonstrated consistent growth over time, mid-2023 saw significant volatility, highlighting the risks inherent in volume-driven trading strategies. Investors are advised to balance exposure with robust risk management protocols when implementing similar approaches.